Coverage and prior authorization of psychotropic drugs under Medicare Part D.

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Abstract Text:

Haiden A Huskamp,David G Stevenson,Julie M Donohue,Joseph P Newhouse,Nancy L Keating,

This study examined formulary coverage and use of utilization management tools for three classes of psychotropic medications (antidepressants, antipsychotics, and anticonvulsants) among Medicare Part D prescription drug plans serving individuals dually eligible for the Medicare and Medicaid programs. Plans must cover "all or substantially all" molecules (distinct drugs) in these classes. Plans serving "dual eligibles" generally covered at least one formulation of all molecules in the three classes. However, certain product formulations were not covered by a number of plans, and use of prior authorization was common for a minority of plans. The effect of Part D will depend on the restrictiveness of the prior authorization and appeals processes, which is currently unknown.

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Publishing Authors By Initials

HA Huskamp,DG Stevenson,JM Donohue,JP Newhouse,NL Keating,

For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

PUBMED ID PMID:

MEDLINE DATE:

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Psychiatric services (Washington, D.C.)

VOLUME: 58

Page Numbers: 308-10

Journal Abbreviation:

ISSN: 1075-2730

DAY: 3

MONTH: Mar

YEAR: 2007

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502838

Coverage and prior authorization of psychotropic drugs under Medicare Part D. Keywords Mesh Terms:

KEYWORDS: United States

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Coverage and prior authorization of psychotropic drugs under Medicare Part D. Information

Substance Name: Psychotropic Drugs

Registry Number: 0

Grant and Affiliation Information for Coverage and prior authorization of psychotropic drugs under Medicare Part D.

AFFILIATION: Department of Health Care Policy, Harvard Medical School, and Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. huskamp@hcp.med.harvard.edu

Country: United States

AGENCY: United States AHRQ

GRANT: P01-HS-10803

ACRONYM: HS

MEDLINETA: Psychiatr Serv

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Coverage and prior authorization of psychotropic drugs under Medicare Part D Related Publications

• Activin-betaA signaling is required for zebrafish fin regeneration.
• Campuses of the LACC.
• Celecoxib : a review of its use in the management of arthritis and acute pain.
• Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
• Colesevelam: a review of its use in hypercholesterolemia.
• Computing van der Waals energies in the context of the rotamer approximation.
• Coupling molecular beacons to barcoded metal nanowires for multiplexed, sealed chamber DNA bioassays.
• Coverage and prior authorization of psychotropic drugs under Medicare Part D.
• Deferasirox : a review of its use in the management of transfusional chronic iron overload.
• Differences in hospice care between home and institutional settings.
• Distance-dependent emission from dye-labeled oligonucleotides on striped Au/Ag nanowires: effect of secondary structure and hybridization efficiency.
• Dr. Tom Lawrence: a life in chiropractic.
• E14 Therapy for CLL: current approach, future trends.
• Gene expression analysis of zebrafish heart regeneration.
• Maraviroc.
• Metallic barcodes for multiplexed bioassays.
• Methods for simulating the dynamics of complex biological processes.
• Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
• Monoclonal antibodies in chronic lymphocytic leukemia.
• On-beam synchrony in the cerebellum as the mechanism for the timing and coordination of movement.
• One size doesn't fit all.
• Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair.
• Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness.
• Revision anterior cruciate ligament reconstruction: timing of surgery and the incidence of meniscal tears and degenerative change.
• Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
• Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
• Silica-coated, Au/Ag striped nanowires for bioanalysis.
• The Homewood influence in Canada and beyond.
• Transcriptional profiling of caudal fin regeneration in zebrafish.
• Using performance data to identify preferred hospitals.